Bartneck, Matthias

Our research focus lies on myeloid cells, specifically macrophages. In the novel rapid model for liver cancer, we have analyzed the mRNA profiles of myeloid infiltrating cells and of tumor-associated macrophages and have discovered several novel functions of the myeloid cell populations in liver cancer.   
Key scientific question: Which are the roles of different myeloid cell for tumor development?


Murine liver disease models:
1 ) Models for hepatitis (inflammation):
a ) Carbon tetrachloride (CCl4)-based models: a single injection of CCl4 leads to liver injury and initiates an infiltration with immune cells into the liver.
b ) Concanavalin-A (ConA)-based models (autoimmune hepatitis): a single injection of ConA leads to stimulation of CD8-T-cells which in lead to pronounced acute liver injury.

2 ) Models for chronic liver injury:
CCl4 is injected twice weekly over the period of 6 weeks which generates liver fibrosis.

3 ) Models for liver cancer:
a ) DEN-based model: Liver cancer is induced by Diethylnitrosamine (DEN) which is administered intraperitoneally into mice 14 days postpartum at 25 mg/kg body weight.
b ) DEN-CCl4-model: We have recently developed a rapid model for liver cancer in which mice injection of DEN mice at the age
of fourteen days. At the age of 8 weeks, mice receive twice weekly injections of CCl4. The strength of this model of liver cancer is the rapid development of autochthonous liver at the age of 24 weeks only.

Technology used:

Cell culture standard equipment, time lapse microscopy, multi-photon-imaging (facility). Flow cytometry (BD FACS Canto, BD FACS Fortessa, cell sorting (BD FACS Aria), Nanostring-based mRNA profiling, Single cell-sequencing-based mRNA profiling of pre-sorted myeloid cells in hepatic inflammation and cancer (10x-Genomics). Non-invasive imaging technology (Micro-computed tomography, Ultrasound-imaging, Fluorescence-based imaging FMT). Currently scintigraphical methods such as SPECT are being established for non-invasive monitoring of myeloid cells.

Key publications related to Mye-EUNITER:

1 ) Bartneck M, Schlößer CT, Barz M, Zentel R, Trautwein C, Lammers T, Tacke F. Immunomodulatory Therapy of Inflammatory Liver Disease Using Selectin-Binding Glycopolymers. ACS Nano. 2017.
2 ) Bartneck M, Scheyda KM, Warzecha KT, Rizzo LY, Hittatiya K, Luedde T, Storm G, Trautwein C, Lammers T, Tacke F. Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases.
3 ) Bartneck M, Peters FM, Warzecha KT, Bienert M, van Bloois L, Trautwein C, Lammers T, Tacke F. Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages.
4 ) Bartneck M, Ritz T, Keul HA, Wambach M, Bornemann J, Gbureck U, Ehling J, Lammers T, Heymann F, Gassler N, Lüdde T, Trautwein C, Groll J, Tacke F. Peptide-functionalized gold nanorods increase liver injury in hepatitis. ACS Nano 2012;6(10):8767-77.
5 ) Bartneck M, Keul HA, Zwadlo-Klarwasser G, Groll J. Phagocytosis independent extracellular nanoparticle clearance by human immune cells.Nano Letters 2010;10(1):59-63.

Contact details:

Dr. rer. nat. Matthias Bartneck 
Department of Medicine III
Pauwelsstrasse 30, 52074 Aachen
University Hospital RWTH Aachen
+49-241-80-80662 +49-241-80-82455